Key Points
- ANI Pharmaceuticals CFO Stephen Carey sold 2,850 shares at an average price of $72.87, totaling $207,679.50. The Rule 10b5-1 transaction reduced his holdings by 1.69%, leaving him with 166,143 shares.
- ANI shares opened at $72.00, down 1.6%, and remain below their 200-day moving average of $77.68. The stock has traded between $69.58 and $95.57 over the past year.
- The company reported quarterly earnings of $2.21 per share and revenue of $266.04 million, beating analyst expectations, while revenue increased 25.8% year over year. Analysts’ average rating is “Hold,” with a consensus price target of $99.60.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CFO Stephen Carey sold 2,850 shares of the firm's stock in a transaction on Thursday, October 29th. The stock was sold at an average price of $72.87, for a total value of $207,679.50. Following the completion of the sale, the chief financial officer directly owned 166,143 shares of the company's stock, valued at $12,106,840.41. The trade was a 1.69% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
ANI Pharmaceuticals Trading Down 1.6%
Shares of NASDAQ:ANIP opened at $72.00 on Friday. The business's 50-day moving average is $72.96 and its 200 day moving average is $77.68. ANI Pharmaceuticals, Inc. has a 1 year low of $69.58 and a 1 year high of $95.57. The firm has a market capitalization of $1.65 billion, a P/E ratio of 15.52, a P/E/G ratio of 2.36 and a beta of 0.50. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts' consensus estimates of $2.04 by $0.17. The company had revenue of $266.04 million during the quarter, compared to analysts' expectations of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%. The firm's revenue was up 25.8% compared to the same quarter last year. During the same period last year, the business posted $1.80 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, research analysts predict that ANI Pharmaceuticals, Inc. will post 7.76 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several equities analysts recently commented on the stock. Weiss Ratings lowered shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday, August 11th. Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 9th. They issued an "outperform" rating and a $104.00 target price for the company. Oppenheimer started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, September 23rd. They set a "market perform" rating and a $85.00 target price on the stock. Wall Street Zen lowered shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, August 8th. Finally, Guggenheim cut their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a research note on Monday, August 10th. Three investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, ANI Pharmaceuticals presently has an average rating of "Hold" and a consensus price target of $99.60.
Check Out Our Latest Stock Analysis on ANIP
Hedge Funds Weigh In On ANI Pharmaceuticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANIP. The Manufacturers Life Insurance Company increased its position in ANI Pharmaceuticals by 1.5% during the first quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company's stock worth $736,000 after buying an additional 143 shares during the period. James Investment Research Inc. lifted its stake in ANI Pharmaceuticals by 4.3% in the third quarter. James Investment Research Inc. now owns 4,850 shares of the specialty pharmaceutical company's stock valued at $352,000 after buying an additional 200 shares during the last quarter. GAMMA Investing LLC lifted its stake in ANI Pharmaceuticals by 13.4% in the third quarter. GAMMA Investing LLC now owns 1,783 shares of the specialty pharmaceutical company's stock valued at $130,000 after buying an additional 211 shares during the last quarter. Versant Capital Management Inc boosted its holdings in shares of ANI Pharmaceuticals by 103.3% in the third quarter. Versant Capital Management Inc now owns 427 shares of the specialty pharmaceutical company's stock valued at $31,000 after acquiring an additional 217 shares during the period. Finally, Yousif Capital Management LLC boosted its holdings in shares of ANI Pharmaceuticals by 5.6% in the third quarter. Yousif Capital Management LLC now owns 5,187 shares of the specialty pharmaceutical company's stock valued at $377,000 after acquiring an additional 275 shares during the period. Hedge funds and other institutional investors own 76.05% of the company's stock.
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with limited competition, complex formulations and specialized manufacturing requirements, serving therapeutic areas that include endocrinology, immunology, ophthalmology, dermatology and central nervous system disorders.
ANI's portfolio includes branded products and generic medicines, as well as treatments for rare diseases.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
